• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
  • Contact
  • About
Monday, June 27, 2022
Maryland Digital News
  • Home
  • US
  • Business
  • World
  • Baltimore
  • Columbia
  • Germantown
  • Waldorf
  • Silver Spring
  • Frederick
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Baltimore
  • Columbia
  • Germantown
  • Waldorf
  • Silver Spring
  • Frederick
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Columbia

Anticancer Drug Shrinks Tumors In Patients With Recurrent Glioblastoma

by NewsReporter
February 7, 2022
in Columbia
Reading Time: 3 mins read
anticancer-drug-shrinks-tumors-in-patients-with-recurrent-glioblastoma
Share on FacebookShare on Twitter

A clinical trial has found that selinexor, the first of a new class of anti-cancer drugs, was able to shrink tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer.

“Glioblastoma is an incurable brain cancer that needs new therapeutic approaches. Considering that few treatments have any measurable effect on recurrent glioblastomas, the results are encouraging,” says the study’s leader, Andrew B. Lassman, MD, the John Harris Associate Professor of Neurology at Columbia University Vagelos College of Physicians and Surgeons and chief of the Neuro-Oncology Division at Columbia University Irving Medical Center/NewYork-Presbyterian(link is external and opens in a new window).

“The drug induces a response in certain patients, and several trial patients stayed on selinexor for more than 12 months, including one for over 42 months,” adds Dr. Lassman, who also is associate director for clinical trials at the Herbert Irving Comprehensive Cancer Center.

The study was published January 10, 2022 in Clinical Cancer Research(link is external and opens in a new window). 

Glioblastomas are typically treated with a combination of surgery, radiation therapy, chemotherapy, and sometimes an electrical device, but the average survival time is just 12 to 18 months.

Selinexor, an oral medication, inhibits, exportin-1 (XPO-1), a major exporter of proteins from the nucleus to cytoplasm that is overexpressed in many cancers, including glioblastoma. Exportin inhibition results in retention of various tumor suppressor proteins in the nucleus, inducing reactivation of tumor suppressor function as well as other antineoplastic effects. Selinexor was approved by the FDA for the treatment of refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma and had pre-clinical activity against glioblastoma models.

Dr. Lassman led the international phase 2 trial to identify the optimal dosing schedule and evaluate the safety and efficacy of selinexor in adults with recurrent glioblastomas whose cancer had progressed following initial treatment.

Reduction in tumor size was observed in 28% of patients, and a tolerable dose was identified for future human trials already ongoing at Columbia and collaborating sites.

The most common treatment-related side effects were fatigue (61%), nausea (59%), decreased appetite (43%), and low platelet counts (43%). All these side effects were manageable with supportive care and dose modification.

There were also a robust set of molecular correlative analyses performed, including an effort led by Andrea Califano, Dr., chair of the Department of Systems Biology at Columbia University Vagelos College of Physicians and Surgeons, to identify a molecular signature in baseline tumor tissue that is predictive of patient benefit from selinexor. Drs. Lassman, Califano, and others are planning a subsequent study to validate this signature in a subsequent trial of patients with newly diagnosed glioblastoma. 

“Taken together, we believe that our findings show that selinexor is an active drug in some patients with glioblastoma and is worthy of further study,” says Dr. Lassman.

An ongoing trial available at Columbia is evaluating the safety and efficacy of selinexor in combination with other therapies for patients with newly diagnosed or recurrent glioblastoma.

Reference: Lassman AB, Wen PY, van den Bent MJ, et al. A Phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma. Clin Cancer Res. 2022;28(3):452-460. doi: 10.1158/1078-0432.CCR-21-2225

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read More Here

Related Posts

taking-back-sunday-to-release-20th-anniversary-edition-of-tell-all-your-friends

Taking Back Sunday To Release 20th Anniversary Edition Of Tell All Your Friends

by NewsReporter
April 14, 2022
0

Taking Back Sunday will reissue their debut album ‘Tell All Your Friends’ to mark the 20th anniversary of the release. ‘Tell All Your Friends’ was released on 26 March, 2002. While the album failed to chart after release, it went on to see over 500,000 copies in the USA after...

villanova-wins-doubles-point-and-two-singles-matches-in-4-3-loss-to-drexel-–-villanova-university

Villanova Wins Doubles Point And Two Singles Matches In 4-3 Loss To Drexel – Villanova University

by NewsReporter
April 13, 2022
0

PHILADELPHIA, Pa.—Villanova (3-13) won the doubles point for the second straight match and claimed a pair of singles victories in a road match against Drexel (8-7) but ultimately fell by the narrowest of margins in a 4-3 loss at the Vidas Courts on Tuesday afternoon. Sophomores Josh Robinson (Potomac, Md.)...

advice-for-primary-care-clinicians-on-use-of-vortioxetine-|-ndt

Advice For Primary Care Clinicians On Use Of Vortioxetine | NDT

by NewsReporter
April 12, 2022
0

Plain Language Summary Diagnosis and management of major depressive disorder (MDD) in a primary care setting Primary care clinicians need practical guidance for the diagnosis and management of MDD, which is a major health concern in the United States. A variety of tools suitable for clinical practice can support primary...

the-look-ahead:-week-3

The Look Ahead: Week 3

by NewsReporter
April 11, 2022
0

Equestrian will compete in the NCEA national tournament starting on Thursday, track will host its first home meet of the year on Friday and women’s rugby will play its first game since winning the national championship in November. by Heath Monsma and Lizzy Strapp | 4/11/22 2:00am Wednesday, April 13...

Maryland Digital News

© 2021 Maryland Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
  • Contact
  • About

Follow Us

No Result
View All Result
  • Home
  • About
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Maryland Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT